AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

For Capstan, AbbVie will pay up to $2.1 billion in cash, subject to certain customary adjustments. Capstan is backed by investors including Pfizer Ventures, Novartis Venture Fund, Eli Lilly and ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the stock jumped 3.4% on the ...

San Diego-based Capstan is developing a potential first-in-class therapy to treat certain autoimmune disease by changing ...

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

AbbVie plans to release Q4 2024 results on Jan. 31. ... AbbVie Builds Momentum With Immunology Growth, ... with double-digit expansion of 10-11% expected in 2026 and 2027.

Wells Fargo analyst Mohit Bansal has maintained their bullish stance on ABBV stock, giving a Buy rating today. Mohit Bansal has given his Buy rating due to a combination of factors that enhance ...

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs ...